title: Detection at diagnosis of tumor cells in bone marrow aspirates of patients with small-cell lung cancer (SCLC) and clinical correlations.
abstract: BACKGROUND
  Immunocytochemistry has often been used to identify tumor cells in bone marrow aspirate (BMA) of SCLC patients in order to improve the results of conventional histomorphology. However, whether the detection of bone marrow microlocalisation at diagnosis had implications for prognosis has not been clear.
  
  
  METHODS
  Eighty-four slides (44 patients) and 66 bone marrow biopsies (from 42/44 patients) were evaluated. Cytospins of BMA were incubated with the monoclonal antibody (MAb) NCC-LU-243, recognising the cluster 1 antigen (NCAM) and then stained by the APAAP (alkaline phosphatase-anti-alkaline phosphatase) method. The relationship among BMA and PS (performance status), NSE (neuron-specific enolase), stage, survival was also studied.
  
  
  RESULTS
  33/84 (39%) BMA were positive for NCAM, compared with 8/66 (12%) bone marrow biopsies (p = 0.009), (17/44 and 6/42 patients, respectively). Moreover, BMA was positive for NCAM in 6/19 patients with limited disease. The presence of positive BMA did not correlate with PS, NSE or stage, but patients with positive BMA had shorter survivals than those with negative BMA (median survival: 7 and 12 months, respectively, p = 0.007).
  
  
  CONCLUSIONS
  Bone marrow involvement detected by immunocytochemistry appears to be related to survival but not to parameters of tumor burden (NSE, stage), suggesting that this technique might help to select patients with better prognoses for new therapeutic strategies.
authors.affiliation: Divisione e Cattedra di Oncologia Medica, Università di Verona, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Pasini
authors.forename: G
authors.initials: G
authors.lastname: Pelosi
authors.forename: R
authors.initials: R
authors.lastname: Mostacci
authors.forename: A
authors.initials: A
authors.lastname: Santo
authors.forename: A
authors.initials: A
authors.lastname: Masotti
authors.forename: P
authors.initials: P
authors.lastname: Spagnolli
authors.forename: E
authors.initials: E
authors.lastname: Recaldin
authors.forename: G L
authors.initials: GL
authors.lastname: Cetto
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology*; D001855:Bone Marrow Diseases / Q000175:diagnosis; D019002:CD56 Antigen; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000473:pathology*; D015816:Cell Adhesion Molecules, Neuronal / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D014408:Biomarkers, Tumor; D019002:CD56 Antigen; D015816:Cell Adhesion Molecules, Neuronal